Dynavax Technologies (DVAX) Q4 2020 Earnings Call Transcript

Joining me on the call today are Ryan Spencer, chief executive officer; Michael Ostrach, chief financial officer; Rob Janssen, chief medical officer; and Donn Casale, senior vice president, commercial. Before we begin, I advise you that we will be making forward-looking statements today, including statements regarding HEPLISAV-B's commercial profile, revenue expectations, potential peak revenue, European launch and the completion of postmarketing studies and regarding vaccine development potential for CpG 1018 and revenue expectations.